London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of ...

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for ...

Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to ...

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to ...

Purespring Therapeutics, a UK-based gene therapy company focused on kidney disease, has raised £80 million ($105 million) in ...

Purespring raises £80 million in a Series B financing, with Syncona committing £19.9 million[1] as part of a leading syndicate of life science investorsProceeds will be used to advance Purespring’s ...

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases ...

A University of Bristol spinout company focused on transforming the way kidney diseases are treated has announced an £80m ...

Syncona is a London-based life science investor that owns a diversified portfolio of companies spanning across clinical stages. Purespring Therapeutics is an investee company of Syncona. It is focused ...

Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by ...

The London-based firm said it will use the funds to advance its gene therapy pipeline, including its lead program in IgA nephropathy.

In this episode of the pharmaphorum podcast, our news editor Richard Staines talks to Richard Francis, who took over as CEO of gene therapy company Purespring Therapeutics earlier this month.